They were also more likely to have more than 10 years of experience practicing oncology (49% versus 31%, p = 0.06) and have higher clinical loads of patients with lung cancer in general (34.8% versus 14.3%, respectively, p = 0.02), of both EGFR-mutated (24.6% versus 8.6%, respectively, p = 0.040) and ALK-translocated patients (30.4% versus 8.6%, respectively, p = 0.008) compared with nonconfident providers. This evidence concerns the gene EGFR and lung carcinoma.